Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Blood 2012 Jul 26;120(2):376-85. Epub 2012 Mar 26.

Comprehensive Cancer Center, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA.

The attrition rate for anticancer drugs entering clinical trials is unacceptably high. For multiple myeloma (MM), we postulate that this is because of preclinical models that overemphasize the antiproliferative activity of drugs, and clinical trials performed in refractory end-stage patients. We validate the Vk*MYC transgenic mouse as a faithful model to predict single-agent drug activity in MM with a positive predictive value of 67% (4 of 6) for clinical activity, and a negative predictive value of 86% (6 of 7) for clinical inactivity. We identify 4 novel agents that should be prioritized for evaluation in clinical trials. Transplantation of Vk*MYC tumor cells into congenic mice selected for a more aggressive disease that models end-stage drug-resistant MM and responds only to combinations of drugs with single-agent activity in untreated Vk*MYC MM. We predict that combinations of standard agents, histone deacetylase inhibitors, bromodomain inhibitors, and hypoxia-activated prodrugs will demonstrate efficacy in the treatment of relapsed MM.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-02-412783DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398763PMC
July 2012
5 Reads

Publication Analysis

Top Keywords

clinical trials
12
multiple myeloma
8
clinical
6
67% clinical
4
predictive 67%
4
activity positive
4
clinical activity
4
positive predictive
4
activity negative
4
86% clinical
4
clinical inactivity
4
predictive 86%
4
agents histone
4
negative predictive
4
histone deacetylase
4
drug activity
4
validate vk*myc
4
deacetylase inhibitors
4
drug-resistant responds
4
end-stage patients
4

Similar Publications